|
Daily Medical Update
Dermatophytes
Sunday, May 17, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Key Findings
- Across 89 included publications, global spread increased to 1215 reported cases outside India across 36 countries, with Europe contributing 545 cases, North America 90, and Oceania 87.
- Imported infections increased across travel corridors, with 50 studies describing imported cases and 11 documenting autochthonous transmission along intra-Asian, Asia-Europe, and Asia-America routes.
📋 Practice Implication: Refractory or widespread dermatophytosis should prompt specific consideration of T. indotineae, especially when travel, migration, or community spread could explain terbinafine-resistant disease.
|
BMC public health (2025) - Systematic Review
Key Findings
- The pooled prevalence of tinea pedis in military personnel was 17% (95% CI: 12-23%) across 25 studies.
- Studies using microscopy plus fungal culture reported higher prevalence estimates than microscopy alone (20% vs 9%), and prevalence was highest in the Americas and Australia.
📋 Practice Implication: Institutional settings with occlusive footwear and shared living quarters warrant prevention programs centered on foot hygiene, footwear practices, and better case detection.
|
Journal of cosmetic dermatology (2025) - Randomized Controlled Trial
Key Findings
- Combination photodynamic therapy plus fractional CO2 laser produced negative mycology in 86.7% of patients, outperforming either modality alone.
- Full nail clearance was achieved in 26.7% of the combination group, while post-treatment satisfaction did not differ significantly between groups (p = 0.198).
📋 Practice Implication: For onychomycosis not responding to conventional treatment, combined PDT and fractional CO2 laser is a reasonable escalation pathway when device access and cost are acceptable.
|
Mycoses (2025) - Randomized Controlled Trial
Key Findings
- Clinical cure was higher with diode laser plus photodynamic therapy than with ciclopirox 8% HPCH nail lacquer (94.1% vs 53.3%, p = 0.008).
- Healing was faster with device-based therapy (3.6 +/- 1.2 months vs 9.2 +/- 1.6 months, p < 0.001), although recurrence reached 33.3% and adverse events occurred in 11.4%.
📋 Practice Implication: Device-based therapy may deliver faster clearance than topical lacquer alone, but patients need counseling about recurrence risk and procedure-related adverse events.
|
Mycoses (2025) - Randomized Controlled Trial
Key Findings
- At 6 weeks, all three itraconazole formulations showed similar short-term clinical response vs each other, with no significant differences in BSA, PGA, or KOH negativity.
- At 3 months, SUBA-ITZ 50 mg had lower relapse and recurrence (10.2%) than SUBA-ITZ 65 mg (31.1% and 28.9%) and conventional itraconazole 100 mg (23.9% and 26.1%) (p < 0.05).
📋 Practice Implication: When oral itraconazole is selected for superficial dermatophytosis, formulation choice may matter more for early relapse prevention than for initial clearance.
|
|
💡
Summary
Recent dermatophyte literature highlights two practical themes: expanding epidemiologic risk from multidrug-resistant Trichophyton indotineae and a growing treatment evidence base for difficult nail and skin disease. Only four first-pass candidates scored above 7, so one next-highest study was included to complete five findings; this suggests the research pool was sparse for the current query and the search terms may need to be broadened. Clinically, clinicians should tighten travel and exposure histories, target prevention in high-risk group settings, and weigh newer adjunctive or device-based strategies when standard therapy is failing or relapse-prone.
|
|